Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma
Clinical trial NCT05268510 · COMPLETED
Trial details
- NCT number
- NCT05268510
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-15
- Primary completion
- 2024-08-27
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.